Combination of cutting-edge IPSC and AI technologies creates opportunity to discover novel metabolic ligands to accelerate drug discovery in rare metabolic diseases

Topics: Corporate, Evotec, Immuneering, metabolic diseases, artificial intelligence, IPSC Read More

$ 6 M payment to access additional cell lines

Topics: Corporate, Evotec, Celgene, IPSC, Induced pluripotent stem cells Read More

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Evotec, Drug Discovery, CENTOGENE, rare genetic diseases, IPSC Read More

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More